ScreenerHero

TRDA Entrada Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · entradatx.com
5.420USD-1.09%Mkt Cap: 211.04M $P/E: —

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considere…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap211.04M USD
Enterprise Value19.53M USD
Revenue (TTM)4.69M USD
Gross Profit-134.36M USD
Net Income (TTM)-143.75M USD
Revenue/Share0.11 USD
Last Price5.420 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees152
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.79
PEG—
EV/EBITDA-0.11
EV/Revenue4.17
P/S44.70
P/B0.83
EPS (TTM)-3.96
EPS (Forward)-3.01
52W Range
5.0803% of range16.45
52W High16.45 USD
52W Low5.080 USD
Profitability
Gross Margin0.00%
Oper. Margin-5007.02%
EBITDA Margin0.00%
Profit Margin-565.48%
ROE-46.96%
ROA-38.09%
Growth
Revenue Growth-53.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.51M USD
CapEx (TTM)1.04M USD
FCF Margin-1657.53%
FCF Yield-36.80%
Net Debt-174.46M USD
Net Debt/EBITDA1.02
Balance Sheet
Debt/Equity0.17
Current Ratio10.89
Quick Ratio10.52
Book Value/Sh6.47 USD
Cash/Share6.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)19.00 USD
Upside (mean)+250.6%
Target Range11.00 USD – 25.00 USD
11.00+250.6% to mean25.00
# Analysts4
Ownership
Shares Out.38.94M
Float22.67M
Insiders12.23%
Institutions82.11%
Short Interest
Short Ratio9.7d
Short % Float10.94%
Short % Out.7.05%
Shares Short2.74M
Short (prev mo.)2.37M
Technical
SMA 506.873 (-21.1%)
SMA 2009.330 (-41.9%)
Beta-0.25
S&P 52W Chg14.58%
Avg Vol (30d)303.04K
Avg Vol (10d)338.66K
Technical Indicators
RSI (14)31.6
MACD-0.3951
MACD Signal-0.2665
MACD Hist.-0.1286
BB Upper7.706 USD
BB Middle6.460 USD
BB Lower5.215 USD
BB Width38.54%
ATR (14)0.4417 USD
Vol Ratio (20d)0.90x